Abstract:Jinjie Gao, 1 Jiajia Zheng, 2 Hua Zhang, 3 Jijun Wang, 1 Hongmei Jing 1 1 Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 2 Department of Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 3 Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China Correspondence: Hongmei Jing, Tel +86-010-82266785, Email Objective: We performed a retrospective analysis to investigate the clinical predictors of bacteremia outcome involving Escherichia coli ( E. coli ) and Klebsiella pneumoniae (K. pneumoniae) after initial empirical antimicrobial therapy among hematological malignancy cases. Methods: This retrospective study was conducted between April 2018 and April 2023. All bloodstream infections (BSIs) caused by E. coli and K. pneumoniae in hospitalized hematological malignancy (HM) patients were identified. Data on patient demographics, clinical characteristics, empirical antimicrobial treatment, outcomes and the antimicrobial susceptibility were collected from medical records. Multivariate analyses were utilized to assess the risk factors for all-cause mortality within 28 days and carbapenem resistance. Optimal cutoffs for continuous predictive variables were evaluated by receiver operating characteristic (ROC) curve analysis. Results: Among 61 individuals diagnosed with bacteremia, 39 cases were caused by E. coli bacteremia, while the remaining 22 were identified as K. pneumoniae bacteremia. Out of these, there were 10 cases of carbapenem-resistant Enterobacteriaceae (CRE) and 12 cases resulted in all-cause mortality within 28 days. Analysis indicated that Pitt score was an independent risk factor for mortality and a cut-off of 2.5 was a reliable predictor with 83.3% sensitivity and 85.7% specificity, respectively. Impaired mental status and elevated body temperature exceeding 38.6°C as well as a procalcitonin (PCT) level over 8.24 ng/mL on the third day (d3) after antimicrobial treatment were identified as independent risk factors for predicting carbapenem resistance. Conclusion: We found that Pitt score with a cut-off of 2.5 was a reliable predictor for mortality within 28 days in HM bacteremia cases. Impaired mental status and elevated temperature exceeding 38.6°C as well as a procalcitonin (PCT) level over 8.24 ng/mL on d3 after antimicrobial treatment were identified as predictive risk factors to carbapenem resistance. Keywords: antimicrobial resistance, mortality, risk factors, initial clinical response Individuals diagnosed with hematological malignancies who have received numerous rounds of chemotherapy are highly susceptible to the development of bloodstream infections (BSIs). Gram-negative bacilli are the primary etiological agents responsible for bloodstream infections (BSIs) in immunocompromised hosts. 1 Carbapenem-resistant Enterobacteriaceae (CRE) bacteremia poses a significant mortality risk and is emerging as a critical concern for individuals with hematological malignancies who are undergoing aggressive chemotherapy regimens or stem cell transplantation (SCT). 2 However, the identification of the specific pathogen in patients with febrile neutropenia often poses challenges. In order to improve sensitivity, it is essential to conduct repeated blood cultures, despite the potential drawbacks of time consumption and relatively low positive culture rates (<20%). 3 Moreover, drug susceptibility reports typically require a few days for completion. Currently, there is limited research on predicting the bacteremia outcome and speculating antimicrobial resistance based on the initial clinical response indicators. Therefore, a retrospective study was conducted to investigate the predictors for carbapenem resistance as well as overall prognosis in cases of bacteremia involving E. coli or K. pneumoniae among patients with HMs. This is a single-center, retrospective, and observational study conducted in hematology department of Peking University Third Hospital, Beijing, China. Adults who were hospitalized with monomicrobial E. coli or K. pneumoniae bacteremia between April 2018 and April 2023 were included. Clinical and demographic data were collected from electronic medical records including the malignancy diagnosis, disease status, comorbidities, exposure of previous chemotherapy, empirical antibiotics administered, vital sign trends, laboratory data, the duration of neutropenia, presentation with septic shock, mental status alte -Abstract Truncated-

Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study

An emergent change in epidemiological and microbiological characteristics of bloodstream infections in adult patients experiencing febrile neutropenia resulting from chemotherapy for acute leukemia and lymphoma at reference centers in Chile, Ecuador, and Peru

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

High mortality associated with inappropriate initial antibiotic therapy in hematological malignancies with Klebsiella pneumoniae bloodstream infections

Epidemiology of Bacteremia in Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplantation and the Impact of Antibiotic Resistance on Mortality: Data from a Multicenter Study in Argentina

Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis

Dissecting bloodstream infections in febrile neutropenic patients with hematological malignancies, a decade-long single center retrospective observational study (2009–2019)

Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients

Clinical Predictors of Bacteremia Outcome After Initial Empirical Antimicrobial Therapy in Patients with Hematological Malignancies: A Retrospective Analysis

Risk of Mortality in Adult Cancer Febrile Neutropenia Patients with a Machine Learning Approach.

Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection

Impact of empirical treatment recommendations of European guidelines for nosocomial pneumonia. A prospective cohort study

Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy

Mortality in patients with hematological malignancies, febrile neutropenia, and septic shock

Clinical and epidemiological characterization of infections in pediatric hemato-oncology patients with febrile neutropenia in the North of Mexico

Bacteremias in Hemato-Oncological Pediatric Patients: Clinical and Microbiological Characteristics

Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy

Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time

Antimicrobial use and appropriateness in neutropenic fever: a study of the Hospital National Antimicrobial Prescribing Survey data

Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients: Insights from the Statistical Analysis of Survey Data